O'Ryan Therapeutics Launches Groundbreaking Parent-Led Pediatric Studies Utilizing YourBio Health’s TAP Capillary Blood Sampling Devices
Today O'Ryan Therapeutics announced it had become the first US company to launch two, parent-led observational studies involving the in-home collection of pediatric blood from children suffering from Juvenile Dermatomyositis (JDM), an ultra-rare pediatric autoimmune disorder, and healthy children. The studies utilize virtually painless TAP Micro devices for capillary blood sampling on a predetermined schedule in addition to event-driven sampling.
The two IRB-approved studies, entitled "The Healthy Kids Study” and “The JDM Study,” empower children along with their families to learn more about their immune health. Guided by animated Superhero Scientists and comic book “mission reports” of their results, children learn about their immune health in an engaging way.
“Today marks ‘one giant leap,’ for pediatric healthcare, opening doors to those who have previously been overlooked in the world of health research,” said Dr. Tim Coleman, COO and Co-founder, O'Ryan Therapeutics. “We understand the challenges families face with distant research sites, which is why we’ve pioneered a method with YourBio Health’s TAP devices that allows for blood sample collection right from the safety and comfort of home.”
🔗 To learn more about O'Ryan Therapeutics, please visit https://oryan.health and read on to learn more about their partnership with YourBio Health here: https://lnkd.in/g5SYC8c4
#PediatricHealthcare
#JuvenileDermatomyositis
#RareDisease
#HealthInnovation
#ORyanHealth
